Keyphrases
Acute Myeloid Leukemia
100%
Azacitidine
95%
High Risk
57%
Overall Survival
44%
Randomized Trial
42%
Intolerant
41%
Reduced-intensity Conditioning
39%
Minimal Residual Disease
38%
Best Available Therapy
38%
Hydroxycarbamide
38%
Ruxolitinib
38%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
31%
Fludarabine
31%
Hematopoietic Stem Cell Transplantation
29%
Complete Remission
28%
Myelodysplasia
28%
T-cell chimerism
25%
Event-free Survival
24%
Phase II Trial
24%
Monotherapy
24%
Intensive Chemotherapy
23%
Annualized Relapse Rate
23%
Immunochemotherapy
22%
Cyclophosphamide
22%
Polycythemia Vera
21%
Hazard Ratio
20%
Transplant Outcomes
19%
Thiotepa
19%
Cachexia
19%
Phase 1/2 Study
19%
Extensive Surgery
19%
Outcome Prediction
19%
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
19%
Arginine
19%
Ultraradical Surgery
19%
Ovarian Cancer
19%
Essential Thrombocythemia
19%
Meta-analysis
19%
Graft-versus-host Disease (GvHD)
19%
Romidepsin
19%
Patient-reported Outcomes
19%
Relapsed or Refractory
19%
TRV027
19%
Steroid-refractory
19%
Eltrombopag
19%
Phase Ib Study
19%
Allograft
19%
Prospective Longitudinal Study
19%
Primary Central Nervous System Lymphoma (PCNSL)
19%
Systematic Meta-analysis
19%
Pharmacology, Toxicology and Pharmaceutical Science
Azacitidine
76%
Acute Myeloid Leukemia
76%
Clinical Trial
61%
Chemotherapy
57%
Overall Survival
52%
Remission
41%
Event Free Survival
38%
Hydroxycarbamide
38%
Ruxolitinib
38%
Fludarabine
31%
Myelodysplastic Syndrome
30%
Diseases
27%
Phase II Trials
23%
Cyclophosphamide
22%
Adverse Event
22%
Polycythemia vera
21%
Cachexia
19%
Thiotepa
19%
Central Nervous System Tumor
19%
Chronic Graft Versus Host Disease
19%
Tamoxifen
19%
Arginine
19%
Melphalan
19%
Romidepsin
19%
Eltrombopag
19%
Thrombocythemia
19%
Lung Cancer
19%
Minimal Residual Disease
19%
Vorinostat
19%
Ibrutinib
19%
Acute Lymphoblastic Leukemia
19%
Posttransplant Lymphoproliferative Disease
19%
Glutamine
19%
Myeloproliferative Neoplasm
19%
D Dimer
19%
Placebo
19%
Progression Free Survival
18%
Cytarabine
17%
Maximum Tolerated Dose
15%
Rituximab
13%
Primary Central Nervous System Lymphoma
11%
Mitoxantrone
11%
Thrombosis
10%
Non Small Cell Lung Cancer
9%
angiotensin[1-7]
9%
Amsacrine
9%
Small Cell Lung Cancer
9%
High Dose Chemotherapy
9%
Busulfan
9%
Blood Clotting Disorder
9%
Medicine and Dentistry
Acute Myeloid Leukemia
76%
Azacitidine
57%
Overall Survival
49%
Clinical Trial
42%
Hematopoietic Stem Cell Transplantation
38%
Fludarabine
31%
Cumulative Incidence
31%
Myelodysplastic Syndrome
30%
Arm
28%
Event Free Survival
26%
Quality of Life
25%
Drug Megadose
22%
Cyclophosphamide
22%
Diseases
21%
Thiotepa
19%
Reduced Intensity Conditioning
19%
Cachexia
19%
Supplementation
19%
Myeloproliferative Neoplasm
19%
Tamoxifen
19%
Phase II Trials
19%
Molecular Diagnosis
19%
Ibrutinib
19%
Melphalan
19%
Systematic Review
19%
Arginine
19%
Romidepsin
19%
Patient-Reported Outcome
19%
Eltrombopag
19%
Meta-Analysis
19%
Ovarian Cancer
19%
Whole Body Radiation
19%
Lung Cancer
19%
Posttransplant Lymphoproliferative Disease
19%
Minimal Residual Disease
19%
Glutamine
19%
Central Nervous System Tumor
19%
Vorinostat
19%
Acute Lymphoblastic Leukemia
19%
Disease
19%
Conditioning
18%
Cytarabine
17%
Adverse Event
15%
Progression Free Survival
14%
Progenitor Cell
13%
Rituximab
13%
Primary Central Nervous System Lymphoma
11%
Induction Chemotherapy
11%
Mitoxantrone
11%
Allogeneic Hematopoietic Stem Cell Transplantation
11%